XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Net Income (Loss) per Common Share | 9 Months Ended
--- | ---
Dec. 31, 2023
Net Income (Loss) per Common Share [Abstract] |
Net Income (Loss) per Common Share | Note 14—Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) attributable to Roivant Sciences Ltd. |  | $ | 5,096,184 |  |  | $ | (352,014 | ) |  | $ | 4,500,041 |  |  | $ | (975,413 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding, basic |  |  | 800,587,716 |  |  |  | 713,319,399 |  |  |  | 776,759,728 |  |  |  | 703,054,773 |
Effect of dilutive common stock equivalents |  |  | 43,873,969 |  |  |  | — |  |  |  | 47,550,285 |  |  |  | — |
Weighted average shares outstanding, diluted |  |  | 844,461,685 |  |  |  | 713,319,399 |  |  |  | 824,310,013 |  |  |  | 703,054,773 |
Net income (loss) per common share, basic |  | $ | 6.37 |  |  | $ | (0.49 | ) |  | $ | 5.79 |  |  | $ | (1.39 | )
Net income (loss) per common share, diluted |  | $ | 6.03 |  |  | $ | (0.49 | ) |  | $ | 5.46 |  |  | $ | (1.39 | )
For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and nine months ended December 31, 2022, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. As of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive:
|  | December 31, 2023 |  |  | December 31, 2022 |
Stock options and performance stock options |  |  | 65,518,394 |  |  |  | 154,631,025 |
Restricted stock units and performance stock units (non-vested) |  |  | 5,422,465 |  |  |  | 22,153,774 |
March 2020 CVARs(1) |  |  | 17,548,368 |  |  |  | 32,011,996 |
November 2021 CVARs (non-vested) |  |  | 359,730 |  |  |  | 3,609,021 |
Restricted common stock (non-vested) |  |  | 238,059 |  |  |  | 730,522 |
Earn-Out Shares (non-vested) |  |  | 3,080,387 |  |  |  | 3,080,387 |
Private Placement Warrants |  |  | — |  |  |  | 10,214,365 |
Public Warrants |  |  | — |  |  |  | 20,475,875 |
Other stock based awards and instruments issued |  |  | 4,147,404 |  |  |  | 6,178,990 |
(1) | Refer to Note 9, “Share-Based Compensation” for details regarding settlement of CVARs.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration